addS

Showing posts with label La Merie Publishing. Show all posts
Showing posts with label La Merie Publishing. Show all posts

Tuesday 2 July 2013

Just Released :Recombinant Coagulation Factors 2013 - The Race to Market and for Market Shares: A Technology & Pipeline Assessment and Corporate Benchmarking Analysis


A Technology & Pipeline Assessment and Corporate Benchmarking Analysis

The report “Recombinant Coagulation Factors 2013 – The Race to Market and for Market Shares: Technology & Pipeline Assessment and Corporate Benchmarking Analysis” of June 2013 describes a market forecast based on growth of historical sales of recombinant coagulation factors. The report evaluates reasons for failures of novel recombinant coagulation factors and provides detailed profiles of active recombinant coagulation factors in clinical development. Preclinical projects are valued on the basis of the underlying technologies. Emerging alternative therapeutic approaches are described and assessed. 




The detailed target pipeline assessments put emphasis on the competitive situation regarding stage of development, inhibitor profile, half-life, administration frequency, clinical success and especially time to approval/market. The pipelines of the clinically active companies are described and their competitive position assessed in light of the key success factors. Sources of information are LMP’s proprietary database, scientific literature (abstracts, papers), corporate information (press releases, presentations, reports, SEC filings). All information is referenced.




Combined product sales of the three classes olf recombinant coagulation factors used in hemophilia were US$ 7.172 mln in 2012. The pipeline of new recombinant coagulation factors is maturing and the first molecules are under regulatory review by the FDA and the EMA and many have entered pivotal clinical studies. There are 46 different molecules and R&D approaches for novel recombinant coagulation factors for hemophilia A and B in the pipeline of which 24 are in clinical development of under regulatory review. Given this tight competition, time-to-market will be an important success. This report will explain the potential development and approval timelines of each of the advanced molecules.


About Us

MarketResearchReports.Biz is the most comprehensive collection of market research reports. MarketResearchReports.Biz services are especially designed to save time and money of our clients. We are a one stop solution for all your research needs, our main offerings are syndicated research reports, custom research, subscription access and consulting services. We serve all sizes and types of companies spanning across various industries.

Contact
M/s Sheela
90 Sate Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-997-4948

Tuesday 7 May 2013

Competitor Analysis: Therapeutic Proteins - Biosimilars, Biobetters & Biosuperiors by MarketResearchReports.biz



Competitor Analysis: Therapeutic Proteins – Biosimilars, Biobetters & Biosuperiors


The new Competitive Intelligence Report Therapeutic Proteins – Biosimilars, Biobetters & Biosuperiors of May 2013 provides a competitor analysis in the product portfolios and development pipelines of ten major classes of therapeutic proteins and their biosimilar and biobetter/biosuperior versions in regulated and less regulated markets:

  • Erythropoietin (EPO) & Erythropoiesis Stimulating Agents (ESA)
  • G-CSF & GM-CSF
  • Thrombopoietin & Thrombopoiesis Stimulating Agents
  • Interferon
  • Insulin
  • Coagulation Factors
  • Human Growth Hormone (hGH)
  • FSH, hCG and LH: Therapeutic Proteins for Assisted Reproductive Technology (ART)
  • Thrombolytics & Fibrinolytics
  • Enzyme Replacement Therapies
Territories covered are the major pharmaceutical markets North America, Europe and Japan, as well as South Korea, India, China and other countries in Latin America, Africa and Australasia.

With more than US$ 50 bln in sales, therapeutic proteins represent a major category of pharmaceutical products with established therapeutic value and high economic attractiveness. As more and more of the branded products are running out of patent protection and regulatory agencies are providing better guidance, development of biosimilar versions as well as of improved next generation versions are a highly attractive goal for pharmaceutical and biotechnology as well as technology focused companies.

 To Read The Complete Report with : http://www.marketresearchreports.biz/analysis/167445

This report includes a compilation of current active projects in research and development of biosimilar and novel biobetter/biosuperior therapeutic proteins as well as non-protein based competitor products and an overview of approved products in regulated and less regulated markets. Competitor projects are listed in a tabular format providing Information on:

  • Drug Codes,
  • Target / Mechanism of Action,
  • Class of Compound,
  • Company,
  • Product Category,
  • Indication,
  • R&D Stage and
  • additional comments with a hyperlink leading to the source of information.


Latest Report: 

Competitor Analysis: Antibody-Drug Conjugates (ADC): http://www.marketresearchreports.biz/analysis/166400 
      
Product description The present Competitive Intelligence Report about Antibody-Drug Conjugates (ADC) / Immunoconjugates provides a competitor evaluation in the field of tumor targeting antibodies conjugated via a linker with a drug payload for treatment of cancer as of April 2013. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report. The emerging therapeutic class of antibody-drug conjugates (ADC) is coming of age. Two approved and marketed ADC drugs utilizing each one of the ...